Stemagen

Stemagen is a privately held embryonic stem cell research company based in La Jolla, California. In January 2008, Stemagen announced that it had become the first company in the world to create and thoroughly document a cloned human embryo using a laboratory technique known as somatic cell nuclear transfer (SCNT), which involves producing an ovum with a donor nucleus. The development of patient-specific embryonic stem cells for human therapeutic use holds promise for treating degenerative conditions such as Alzheimer’s disease and Parkinson’s disease. Stemagen’s work since its breakthrough announcement has been focused on advancing the cloning process for human embryos, but progress has been slowed by legal challenges surrounding egg donation and funding restrictions under the grant guidelines of the California Institute for Regenerative Medicine ...